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Haematopoietic focal adhesion kinase deficiency
alters haematopoietic homeostasis to drive
tumour metastasis
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Metastasis is the main cause of cancer-related death and thus understanding the molecular
and cellular mechanisms underlying this process is critical. Here, our data demonstrate,
contrary to established dogma, that loss of haematopoietic-derived focal adhesion kinase
(FAK) is sufficient to enhance tumour metastasis. Using both experimental and spontaneous
metastasis models, we show that genetic ablation of haematopoietic FAK does not affect
primary tumour growth but enhances the incidence of metastasis significantly. At a molecular
level, haematopoietic FAK deletion results in an increase in PU-1 levels and decrease in
GATA-1 levels causing a shift of hematopoietic homeostasis towards a myeloid commitment.
The subsequent increase in circulating granulocyte number, with an increase in serum
CXCL12 and granulocyte CXCR4 levels, was required for augmented metastasis in mice
lacking haematopoietic FAK. Overall our findings provide a mechanism by which haemato-
poietic FAK controls cancer metastasis.
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U
nderstanding the molecular and cellular basis of metas-
tasis still remains a major challenge in current cancer
research. Focal adhesion kinase (FAK) is a cytoplasmic
protein-tyrosine kinase that localizes mainly at focal adhesion
sites, and is one of the central players in integrin and growth
factor receptor mediated signalling1,2. FAK also has important
non-kinase functions3. FAK is overexpressed in many human
cancer cells and has thus emerged as an anticancer target4–8. This
has led to the development of FAK inhibitors although off-target
effects are apparent9–11. Moreover, evidence suggests that FAK
may have pleiotropic effects and some work has pointed to FAK
being a negative regulator of metastasis. For example, a study of
cervical cancer has shown that even though FAK expression
was found to be upregulated in tumour cells when compared
with normal cervical epithelium, weak FAK expression was
significantly correlated with poor overall survival12. In addition,
Zheng et al.13 have suggested that FAK-dephosphorylation in
tumour cells is important for Ras-mediated metastasis. These data
suggest that FAK may not be required for metastasis and that the
precise role for FAK in metastasis may be more complex than
initially thought. They also raise the question of the importance of
stromal FAK in the metastatic process.
The tumour stromal compartment has been shown to have an
important role in metastasis14–16. Within the tumour stroma,
bone marrow-derived cells, specifically myeloid, have been
identified as regulators of tumour invasiveness and implicated
in organ-specific tumour metastasis17,18. A heterogeneous popu-
lation of cells that comprises myeloid progenitor cells and
immature myeloid cells, also named myeloid-derived suppressor
cells (MDSCs), has been correlated with clinical stage and
metastatic burden19,20. MDSCs are a mixture of myeloid cells
with characteristics of monocytes and granulocytes and are
generally described by the co-expression of the mouse markers
CD11b and Gr1 (CD11bþGr1þ )21,22. Their expansion at meta-
static sites generates an immunosuppressive niche that suppresses
T cell activation, proliferation and cytotoxicity and also sup-
presses NK cell cytotoxicity23–26. These cells have been shown to
facilitate tumour cell seeding and colonization at metastatic sites
and are thereby thought to drive metastasis27–29.
In short, analysis of tumour cells has suggested that FAK is
required for tumour metastasis, but the role of stromal or
haematopoietic-derived FAK in this process is poorly understood.
We have tested the requirement of haematopoietic FAK in
metastasis using genetic ablation approaches in combination
with haematopoietic transplant experiments. Here we establish
that decreased expression of FAK in the haematopoietic com-
partment generates a pro-metastatic microenvironment that
actually enhances tumour cell colonization and metastasis. Our
data highlight a role for haematopoietic FAK as a negative, rather
than positive, regulator of tumour cell metastasis via the control
of haematopoietic homeostasis and mobilization of CD11bþ
Gr1þ cells.
Results
FAK deletion increases metastases in the RIP-Tag2 model. A
genetic approach was used to ablate FAK globally to study the
effect of FAK deletion on tumour metastasis. We generated a
tamoxifen-inducible model for FAK deletion in adult mice,
RERTnERT/ERTCre;FAKfl/fl and confirm efficient FAK deletion at
the protein level in this system (Supplementary Figs 1A–D,
2A, B)30–32. RERTnERT/ERTCre mice have been used previously
to induce global deletion of target genes31. Non-induced
RERTnERT/ERTCre;FAKfl/fl mice were viable and fertile with no
obvious defects. The effect of FAK deletion on metastasis was first
analysed in RIP-Tag2 mice, a well-studied, spontaneous model of
pancreatic cancer that expresses the SV40 T antigen (Tag) under
the control of the rat insulin promoter33. Expression of Tag in
pancreatic islet b-cells leads to the development of hyperplastic
lesions at 6–8 weeks of age of which a fraction will progress into
highly vascularized b-cell tumours at 10–14 weeks of age. These
tumours have been reported to invade and spread to lymph
nodes and liver34. RIP-Tag2 mice die by 16 weeks of age33.
RIP-Tag2 mice were crossed with RERTnERT/ERTCre;FAKfl/fl
(RERTFAKKO) or control FAKfl/fl (RERTFAKWT) mice generat-
ing RIP-Tag2;RERTFAKKO and RIP-Tag2;RERTFAKWT mice
respectively. Mice were treated with tamoxifen from 9 weeks of
age to induce FAK deletion in both tumour and stromal com-
partments. Total pancreatic tumour burden was not statistically
different between genotypes at 15 weeks of age (Fig. 1a).
Pancreatic tumours in RIP-Tag2 mice are classified into three
levels of progression: encapsulated, the least aggressive form;
invasive type I, where the invasive front of the tumour begins to
penetrate into the surrounding pancreas; and invasive type II,
where the invasive front of the tumour engulfs islands of normal
pancreas34,35. Quantification of Tag-positive pancreas sections
revealed that FAK deletion had no significant effect on tumour
invasiveness (Fig. 1b). Histological analysis of metastases to the
peri-pancreatic lymph nodes also showed no statistically significant
differences between genotypes in incidence of metastasis or percen-
tage of lymph nodes with metastases (Supplementary Fig. 3A). In
contrast the incidence of metastases and number of metastases
per liver were significantly higher in RIP-Tag2;RERTFAKKO
when compared with RIP-Tag2;RERTFAKWT mice (Fig. 1c–e).
These data show that when FAK is deleted globally, RIP-Tag2
primary tumour burden is not affected but metastasis is
enhanced.
Stromal FAK deficiency increases experimental metastasis.
Tumour growth and metastasis is regulated not only by the
tumour cells themselves but also by the host or stromal com-
partment. To dissect the role of FAK within the host or stromal
compartment from that in the tumour compartment, an experi-
mental metastasis approach was employed. Syngeneic mouse B16
melanoma cells, which express FAK, were injected via the tail vein
into RERTFAKKO and RERTFAKWT mice. At 19 days post B16
cell injection, significantly elevated numbers of metastatic nodules
were observed in several organs including the lungs, liver and
bones of RERTFAKKO mice when compared with controls
(Fig. 2a). Sections of tissues were stained with haematoxylin and
eosin and metastases counted. Results showed a significant
increase in the total number of metastases in RERTFAKKO mice
when compared with controls (Fig. 2b–d). These data indicate
that loss of FAK in the stromal compartment is sufficient to
increase experimental B16 tumour metastasis.
Haematopoietic FAK deletion increases RIP-Tag2 metastases.
Tumour cell survival in the circulation, seeding at distant sites,
invasion and dissemination are all processes dependent on the
tumour microenvironment. These processes have been shown to
involve many cell types but the molecular mechanisms under-
lying the role of bone marrow-derived cells is still unclear18,36. To
dissect the requirement of FAK within the haematopoietic
compartment from that in the whole stromal compartment, we
undertook an adoptive transfer approach. Briefly, lethally
irradiated 6-week-old female RIP-Tag2 mice were transplanted
with bone marrow from either male RERTnERT/ERTCre;FAKfl/fl or
control FAKfl/fl cre negative mice generating RIP-Tag2;BMFAKKO
and RIP-Tag2;BMFAKWT chimeras, respectively. Two weeks after
bone marrow transplantation, mice were treated with tamoxifen
to induce FAK deletion predominantly in the haematopoietic
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compartment. At 16 weeks of age, necropsies were performed
and showed that RIP-Tag2;BMFAKKO mice had no significant
difference in pancreatic tumour burden when compared with
RIP-Tag2;BMFAKWT controls (Fig. 3a). It is noteworthy that
tumour burden in both genotypes was lower than predicted for
RIP-Tag2 mice at this age most likely because the animals were
irradiated, as reported previously37. Quantification of Tag
immunostained pancreas sections revealed that haematopoietic
FAK deletion had no significant effect on tumour invasiveness
(Fig. 3b) suggesting that haematopoietic FAK is not sufficient to
modulate primary tumour growth or invasion per se. Histological
analysis of metastases to the peri-pancreatic lymph nodes showed
very low numbers of lymph node metastases in both genotypes
and no statistically significant differences between them (Supple-
mentary Fig. 3B). Despite this, the incidence of liver metastasis
was significantly higher in RIP-Tag2;BMFAKKO when compared
with RIP-Tag2;BMFAKWT mice (Fig. 3c,d). Unexpectedly,
RIP-Tag2;BMFAKKO mice also presented an increased incidence
of lung metastases, an organ that has not been previously reported to
display RIP-Tag2 metastasis (Fig. 3c,d). The overall incidence of
metastasis was statistically increased in RIP-Tag2;BMFAKKO
mice when compared with RIP-Tag2;BMFAKWT controls
(Fig. 3d). These data from a spontaneous model of cancer show
that deficiency of haematopoietic FAK is sufficient to enhance
tumour metastasis.
Haematopoietic FAK deletion increases B16 metastases. We
next tested the effect of haematopoietic FAK deficiency on
experimental tumour metastasis by injecting B16 mouse mela-
noma tumour cells in the tail vein of BMFAKWT and BMFAKKO
mice. Results showed that deficiency of FAK in the haemato-
poietic compartment alone was sufficient to increase the number
of tumour metastases in BMFAKKO mice significantly when
compared with controls (Fig. 4a). The presence of this increased
number of metastases was confirmed by histological analysis of
the lungs, liver and bones from BMFAKKO mice and respective
controls (Fig. 4b). Quantification revealed a significant increase in
the number of B16 nodules not only in BMFAKKO lungs, but also
in the livers and bones of these mice when compared with con-
trols (Fig. 4c,d). Validation of the adoptive transfer approach is
given in Supplementary Figs 2C and 4. Together, these data
indicate that the loss of stromal FAK, solely within the haema-



































































































Figure 1 | FAK deficiency enhances metastasis in the RIP-Tag2 model. RIP-Tag2;RERTFAKWT and RIP-Tag2;RERTFAKKO mice started tamoxifen treatment
at 9 weeks of age and were necropsied at 15 weeks of age. Histological analysis was performed in five different depth areas 100mm apart of pancreas and
liver with immunohistochemical staining for the tumour marker SV40 T antigen (Tag). (a) Primary tumour burden in RIP-Tag2;RERTFAKWT and RIP-
Tag2;RERTFAKKO mice. Bar chart represents the total macroscopic tumour burdenþ s.e.m., n¼ 10–13 mice per genotype. Representative images of Tag
immunostained sections primary tumours are shown. NS, not statistically significant, Student’s t-test. (b) Histological images of Tag immunostained
tumour sections at different stages of invasiveness are shown. Quantification of tumour invasiveness is presented as the percentage of encapsulated islet
tumours (encapsulated), microinvasive carcinomas (invasive type I), and fully invasive carcinomas (invasive type II) in RIP-Tag2;RERTFAKWT and RIP-
Tag2;RERTFAKKO mice. NS, not statistically significant, Mann–Whitney test. (c) Representative images of Tag-positive liver metastases. Bar charts
represent (d) incidence of metastasis to the liver or (e) number of metastases per liver. Scale bars, (a) 500mm, (b) 200mm, (c)50mm. *Po0.05;
**Po0.01; Mann–Whitney test.
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A recent paper by Catena et al.38 showed that expression of
thrombospondin—1 (Tsp-1) by Cd11bþGr1þ cells generates a
metastatic refractory microenvironment. In line with this study
we have observed lower levels of Tsp-1 in bone marrow from
RERTFAKKO animals that show increased numbers of metastases
(Supplementary Figs 5A and 6A). In the same study, tumours
cells that secrete prosaposin (Psap) induce Tsp-1 expression in
CD11bþGr1þ cells causing them to behave as metastasis
refractory cells38. To assess the relevance of prosaposin in our
system, we first analysed prosaposin levels in B16F0 and B16F10
tumour cells used in our study. Both B16F0 and B16F10 showed
no detectable levels of prosaposin and we saw no effect of
introducing prosaposin in the phenotypes observed in BMFAKKO
mice; thus we conclude that, for the purposes of our experiments,
prosaposin is unlikely to be involved (Supplementary Figs 5B–D
and 6B–C).
FAK deficiency shifts HSCs towards a myeloid commitment.
Our results suggest that metastasis is enhanced in mice lacking
haematopoietic FAK. It is conceivable that loss of FAK could be
compensated for by the upregulation of other functionally related
molecules. Pyk2 is a member of the FAK family of tyrosine
kinases and has been shown to compensate for FAK loss in
previous studies39–41. Western blot analysis of haematopoietic
lysates from RERTFAKKO and RERTFAKWT mice showed no
significant changes in the levels of Pyk2 between genotypes
(Supplementary Fig. 7). In addition the expression levels of other
focal contact proteins such as paxillin, vinculin and talin were also
unchanged between RERTFAKKO and RERTFAKWT samples
(Supplementary Figs 2D and 7). These data suggest that at least
these candidate genes were unlikely to be compensating for the
loss of FAK.
To understand the mechanism that drives the increased meta-
stasis in the absence of FAK we sought to phenotypically
characterize the haematopoietic compartment of RERTFAKWT
and RERTFAKKO mice. The role of bone marrow-derived cells in
tumour progression and metastasis has been studied extensively,
but the role of FAK in this process is not known18,29,36. Recent
evidence has suggested that FAK can regulate haematopoietic
homeostasis in the bone marrow42. Using flow cytometric analysis
we have characterized haematopoietic stem cells (HSCs) and
committed progenitors in bone marrow from RERTFAKWT and
RERTFAKKO mice (Fig. 5a). We observed an increase in pheno-
typically defined long-term repopulating stem cells LT-HSCs (Linlow
c-kitþ Sca-1þ CD34 Flk-2 ) in RERTFAKKO mice when com-
pared with RERTFAKWT control mice with only a tendency for an
increase in short-term repopulating stem cells ST-HSCs (Linlow
c-kitþ Sca-1þ CD34þ Flk-2 ; Fig. 5b,c). No differences were















































































































Figure 2 | Loss of stromal FAK increases experimental metastasis. RERTFAKWT and RERTFAKKO mice were injected via the tail vein with B16 mouse
melanoma tumour cells and analysed 19 days post inoculation. Metastases in lungs, liver and bones of RERTFAKWT and RERTFAKKO mice: (a) Macroscopic
images and (b) representative images of haematoxylin and eosin stained sections. (c) Bar chart represents the mean number of metastases per
mouseþ s.e.m. (d) Bar charts show mean number of metastases to the lung, liver or boneþ s.e.m., n¼ 10–12 mice per genotype. BM, bone marrow;
CB, calcified bone; Met, metastases; white arrow, metastases. Scale bars, (a) 1 cm; (b) 200mm. *Po0.05; **Po0.01, Mann–Whitney test.
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CD34þ Flk-2þ ; Supplementary Fig. 8A). Analysis of bone marrow-
committed progenitors shows an increase in common myeloid
progenitor CMP (Linlow c-kitþ Sca-1 CD34þ CD16/32mid) in
RERTFAKKO when compared with RERTFAKWT mice (Fig. 5d).
No differences in other bone marrow-committed progenitors, such
as common lymphoid progenitor CLP (Linlow c-kitmid Sca-1mid
CD127þ ), granulocyte-monocyte progenitor GMP (Linlow c-kitþ
Sca-1 CD34þ CD16/32bright) or megakaryocyte and erythroid
progenitors MEP (Linlow c-kitþ Sca-1 CD34þ CD16/32low) were
observed between genotypes (Supplementary Fig. 8B–D)43. These
data suggest that FAK-deficient HSCs are predisposed to a myeloid
commitment. To test this hypothesis, we sorted HSCs (Linlow c-kitþ
Sca-1þ ) from the bone marrow of RERTFAKWT and RERTFAKKO
mice and analysed transcription factors involved in myeloid com-
mitment by real time PCR. PU.1 is a transcription factor critically
responsible for the activation of myeloid-specific promoters, such as
murine neutrophil elastase, granulocyte colony stimulating factor
(G-CSF), macrophage (M)-CSF and GM-CSF promoters44,45.
On the other hand, GATA-1 expression has been shown to
suppress the myeloid expression program46,47. FAKKO HSCs had
increased PU.1 and decreased GATA-1 expression, when compared
with controls. (Fig. 5e–g). Together these data show that FAK
deletion shifts HSC transcriptional programme towards myeloid
lineage commitment.
Loss of BM FAK induces a pro-metastatic microenvironment.
Granulocytes or polymorphonuclear cells (CD11bþ
Gr1hiLy6Cloþ int—PMN) have a short half-life, are quickly
mobilized into the circulation and are considered the best indi-
cator of changes in haematopoietic homeostasis48,49. The increase
in common myeloid progenitor was reflected in the periphery by
elevated numbers of PMN cells in the blood and spleen of
RERTFAKKO mice in the steady state and at various stages after
tail vein injection of tumour cells. Increased numbers of
granulocytes were observed in the blood (Fig. 6a) and spleen
(Fig. 6b) of unchallenged RERTFAKKO mice, 2–5 h after tumour
cell injection (time for tumour cell homing), 24 h after tumour
cell injection (time for tumour cell colonization) and at the
experimental end point (time of tumour cell establishment). We
also observed similar changes in the monocytic fraction of
CD11bþGr1þ cells (CD11bþGr1loþ intLy6Chi—Mon) but to a
lesser extent (Supplementary Fig. 8E–G). Our data establish that
loss of haematopoietic FAK alters haematopoietic homeostasis
and increases CD11bþGr1þ cell mobilization and numbers into
the circulation.
Given the increased mobilization and expansion of the
CD11bþGr1þ cells in the blood and spleen at early time points
after tumour cell injection, we next analysed whether an increase




























































































Figure 3 | Haematopoietic FAK deficiency enhances RIP-Tag2 metastases. RIP-Tag2 mice were transplanted at 6 weeks of age, and tamoxifen treated 2–3
weeks thereafter generating RIP-Tag2;BMFAKWT and RIP-Tag2;BMFAKKO chimeras. Mice were necropsied at 16 weeks of age. Histological analysis was
performed in six different depth areas 100mm apart of pancreas, liver and lungs with immunohistochemical staining for the tumour marker SV40 T antigen
(Tag). (a) Tumour burden in RIP-Tag2;BMFAKWT and RIP-Tag2;BMFAKKO mice. Bar chart represents the proportion of tumour burden as a % of tumour area
per animal normalized to total pancreas areaþ s.e.m., n¼ 7–13 mice per genotype. NS, not statistically significant, Mann–Whitney test. (b) Quantification
of tumour invasiveness is presented as the percentage of encapsulated islet tumours (encapsulated), microinvasive carcinomas (invasive type I), and fully
invasive carcinomas (invasive type II) in RIP-Tag2;BMFAKWT and RIP-Tag2;BMFAKKO mice. NS, not statistically significant, Mann–Whitney test. Scale bar,
200mm. (c) Representative images of Tag immunostained sections of liver and lung. Metastases to liver and lungs are shown. Scale bar, 50mm. (d) Bar
charts represent incidence of metastasis to either liver or lung or total percentage of animals with metastases. wPo0.058; *Po0.05; **Po0.01, Mann–
Whitney test.
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Immunofluorescence for Gr1 showed increased numbers of Gr1þ
cells in the lungs of RERTFAKKO and BMFAKKO mice, 2–5 h
post tumour cell injection, when compared with RERTFAKWT
and BMFAKWT controls, respectively (Fig. 6c,d). An increased
number of Gr1þ cells has been correlated previously with
enhanced metastasis27–29. In parallel we noted a decrease in
infiltration of CD4þ and CD8þ T cells at early time points after
tumour cell injection (Supplementary Fig. 9A–D), but no differ-
ences in NK cell infiltrate in the lungs of RERTFAKKO or
BMFAKKO mice when compared with controls (Supplementary
Fig. 9E, F). Since no changes in CLP were observed in the bone
marrow (Supplementary Fig. 8B), it is possible that these T cell
changes are a consequence of the increased Gr1þ cell numbers
as the latter have been shown previously to have immune
suppressive properties23,24.
Metastasis and neutrophil recruitment are dependent on complex
cytokine networks. Analysis of serum cytokine levels after tumour
cell injection by protein cytokine arrays showed increased levels
of CXCL12 in the serum of RERTFAKKO mice (Fig. 6e). This
coincided with a significant increase in CXCR4 mRNA levels in
FAKKO PMNs recruited to the lung after tumour cell injection
(Fig. 6f,g). CXCL12-CXCR4 axis is involved in metastasis and
neutrophil homing25,50,51. The higher levels of CXCR4 expression
in FAKKO PMN cells suggest that these cells may have increased
propensity to respond to pro-metastatic cytokines such as
CXCL12 and home to sites of metastasis. In addition, other
inflammatory cytokines such as the complement component
C5/C5a was found increased in the serum of RERTFAKKO mice
(Supplementary Fig. 9G). C5/C5a has previously been shown to
be involved in neutrophil recruitment and lung inflammation
preceding lung metastasis52,53. Taken together these data suggest
RERTFAKKO mice present a microenvironment that favours the
recruitment of PMN to metastatic sites.
Gr1 cells govern tumour cell colonization in RERTFAKKO
mice. FAK deficiency in the haematopoietic compartment
resulted in changes in the inflammatory microenvironment that
facilitated recruitment of PMN to metastatic sites at early time
points after tumour cell injection. To test whether these changes
could have an impact on tumour cell homing or colonization, key
steps in metastasis, red cell tracker-labelled tumour cells were
injected into the tail vein of RERTFAKWT, RERTFAKKO,
BMFAKWT and BMFAKKO mice and lungs harvested 2–5 h (to test
for homing) and 48 h (to test for colonization) thereafter. Although
there were no differences in the numbers of tumour cells homing in
the lungs 2–5 h post injection, a significant increase in tumour cell
colonization at 48 h post injection was observed in RERTFAKKO
and BMFAKKO mice when compared with RERTFAKWT and
BMFAKWT controls (Fig. 7a,b). Analysis of Ki67 showed that the
majority of cells were not proliferating at 48 h post injection and
there were no differences between RERTFAKWT and RERTFAKKO
mice, suggesting FAK deletion affected the seeding of tumour cells













































































































Figure 4 | Haematopoietic FAK deletion increases B16 metastasis. BMFAKWT and BMFAKKO mice were injected with B16 mouse melanoma tumour cells
via the tail vein in experimental metastasis experiments and analysed 15–17 days post tumour cell injection. Metastases in lungs, liver and bones from
BMFAKWT and BMFAKKO mice: (a) Macroscopic images and (b) representative images of haematoxylin and eosin stained sections. (c) Bar chart shows
mean number of metastases per mouse,þ s.e.m. (d) Bar charts show mean number of metastases to the lung, liver and boneþ s.e.m., n¼ 9 mice per
genotype. BM, bone marrow; CB, calcified bone; Met, metastases; white arrow, metastases. Scale bars, (a) 1 cm; (b) 200mm. *Po0.05; **Po0.01,
Mann–Whitney test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6054
6 NATURE COMMUNICATIONS | 5:5054 | DOI: 10.1038/ncomms6054 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
To examine the direct requirement of Gr1þ cells in tumour
cell colonization, RERTFAKWT and RERTFAKKO mice were
given two doses of a Gr1-blocking antibody (RB6-8C5), to deplete
Gr1þ cells one day before and on the day of B16 melanoma cell
injection via the tail vein. An isotype-matched antibody was used
as a negative control. Efficient depletion of Gr1þ cells was con-
firmed at 2–5 and 48 h post tumour cell injection (Supplementary
Fig. 10B). The control antibody treatment had no effect on the
increased colonization observed previously in RERTFAKKO mice
when compared with RERTFAKWT controls. Gr1þ cell depletion
had small effect in RERTFAKWT animals but, however, had
decreased tumour cell colonization in RERTFAKKO mice
(Fig. 7c,d). These data suggest that the elevated number of
Gr1þ cells in mice lacking stromal FAK is a critical regulator of
the elevated tumour metastasis observed. In addition, RERTFAKWT
and RERTFAKKO mice were given a Cxcr4 inhibitor AMD3100
or phosphate-buffered saline (PBS) as a control on the day of B16
melanoma cell injection via the tail vein. Cxcr4 inhibition was
sufficient to decrease blood granulocyte levels soon after tumour
cell injection (Fig. 7e). Importantly Cxcr4 inhibition had no
effect in RERTFAKWT but decreased RERTFAKKO tumour cell
colonization (Fig. 7c,f). Together these data suggest that Gr1 cell
numbers and Cxcr4 signalling are important drivers for the
increased tumour cell colonization observed in the absence of
stromal FAK.
Discussion
Here we show that loss of FAK in the haematopoietic com-
partment is sufficient to augment metastasis. This is unexpected
and highlights a mechanism by which metastasis is regulated.
The overexpression of FAK in cancer cells, combined with it
essential role in cell migration, has implicated this molecule as a
positive regulator of cancer progression5,54,55. High levels of both
FAK and Src can be indicative of poor prognosis and tumour
recurrence in a variety of cancers5 and these data have been
interpreted to suggest that inhibitors of FAK may control cancer
growth and progression. Indeed several reports have shown that
inhibition of FAK, often in combination with the inhibition of
other targets, can suppress tumour growth and metastasis9–11.
In contrast, possible negative roles for FAK in tumour progres-
sion have also been reported12,13. For example, FAK expression is
not a prognostic marker for colon adenocarcinoma patients and
FAK expression does not correlate with survival56; loss of tumour
FAK is actually associated with increased metastasis in cervical
cancer12; pharmacological inhibition of Src can suppress meta-
stasis without affecting FAK activation57; and under some
oncogenic conditions, such as those initiated by Ras, metastasis
is promoted by dephosphorylating FAK13.
Although various mechanisms have been discussed to explain
how tumour cell FAK might control metastasis, what was not
known was whether the absence of FAK in the stromal, and
especially in the haematopoietic compartment, has any impact on
metastasis. In contrast to previous data examining the tumour cell
compartment, using a genetic ablation approach our data show
that loss of stromal, and in particular, haematopoietic FAK is
sufficient to actually enhance tumour metastasis. This implies that
we may need to change our concept of FAK to reflect its
potentially counteractive and pleiotropic roles during metastasis.
In addition, although haematopoietic FAK deficiency was























































































































































Figure 5 | FAK deficiency shifts HSCs towards a myeloid commitment. Single-cell suspensions of bone marrow from RERTFAKWT and RERTFAKKO mice
were analysed by flow cytometry. (a) Long-term bone marrow-derived haematopoietic stem cells, LT-HSC (Linlow c-kitþ Sca-1þ CD34 Flk-2 ), short-
term bone marrow-derived haematopoietic stem cells, ST-HSC (Linlow c-kitþ Sca-1þ CD34þ Flk-2 ) and common myeloid progenitors, CMP (Linlow
c-kitþ Sca-1 CD34þ CD16/32mid) in the BM of RERTFAKWT and RERTFAKKO mice were compared. Representative dot blots are shown. Bar charts show
fold change of bone marrow LT-HSC (b) ST-HSC (c) and CMP (d)þ s.e.m., n¼ 10–13 mice per genotype. (e–g) HSCs (Linlow c-kitþ Sca-1þ ) were sorted
from the bone marrow of RERTFAKWT and RERTFAKKO mice, RNA extracted and reversed transcribed into cDNA. Bar charts show mean (e) FAK, (f) PU.1
and (g) GATA-1 mRNA levelsþ s.e.m. quantified by real time PCR, n¼ 3–4 mice/genotype. *Po0.05; **Po0.01; ***Po0.001, Student’s t-test.
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tumour size or invasiveness suggesting that this initial step
of tumorigenesis is not dependent on haematopoietic FAK.
Furthermore, our data also show that genetic ablation of FAK in
both the stromal and cancer compartments simultaneously also
results in enhanced metastasis suggesting that loss of FAK
globally is not sufficient to reduce metastasis.
Our data imply that haematopoietic FAK acts as a negative
regulator of metastatic dissemination and raise the question of
which cells are responsible for this phenotype. Haematopoietic
homeostasis is dependent on HSCs that have the ability to self
renew and maintain lineage differentiation potential58,59 and it
has been hypothesized that disrupting interactions between HSCs
and bone marrow stroma affects HSC fate60–62. Here, we
observed that the absence of stromal FAK induced an increase
in numbers of LT-HSCs and CMP within the bone marrow.
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Figure 6 | Stromal FAK deficiency induces PMN changes. Single-cell suspensions of (a) blood and (b) spleen from RERTFAKWT and RERTFAKKO mice that
were either unchallenged or 2–5 h, 24 h and 15 days post tumour cell injection via the tail vein were analysed by flow cytometry. Bar charts show numbers
of CD45þCD11bþGr1hiLy6Clo (PMN) in blood and spleen from RERTFAKWT and RERTFAKKO mice. n¼ 3–4 mice per genotype. (c,d) B16 tumour cells,
previously labelled with red cell tracker CMTPX, were injected via the tail vein into RERTFAKWT, RERTFAKKO, BMFAKWT and BMFAKKO mice. Then 2–5 h
post injection, lungs were processed and sections immunostained for Gr1þ cells. (c) Representative images of B16 tumour cells (red) and Gr1þ cells
(green) in RERTFAKWT, RERTFAKKO, BMFAKWT and BMFAKKO lung sections 2–5 h after tumour cell injection. (d) Gr1þ cell infiltration into the lungs in
RERTFAKWT, RERTFAKKO, BMFAKWT and BMFAKKO mice. Bar charts represent number of Gr1þ cell per mm2 of lung sectionþ s.e.m., n¼4–5 mice per
genotype. (e) Serum levels of CXCL12 in RERTFAKWT and RERTFAKKO mice 24 h after tumour cell injection. Bar chart represents fold change relative to
RERTFAKWTþs.e.m. (f,g) CD45þCD11bþGr1hiLy6Clo (PMN) cells were sorted from the lung of BMFAKWT and BMFAKKO mice 24 h after tumour cell
injection, RNA extracted and reversed transcribed into cDNA. Bar charts show mean FAK (f) and CXCR4 (g) mRNA levelsþ s.e.m. quantified by real time
PCR, n¼8–10 mice per genotype. Scale bar, 100mm. NS, not statistically significant; *Po0.05; **Po0.01; ***Po0.001, Student’s t-test.
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factor PU.1 and lower levels of GATA-1—both hallmarks of
commitment to a myeloid lineage44–47. Interestingly FAK has
been shown to regulate other GATA family transcription
factors63. This shift towards myeloid lineage commitment did
not correlate with compensation within the bone marrow by
Pyk2, or other focal contact proteins such as vinculin, paxillin or
talin. Instead, our data established that loss of haematopoietic
FAK can deregulate the HSC niche, an observation that is
supported by recently published work demonstrating that
FAK is preferentially expressed in HSCs and that loss of
bone marrow FAK in Mx1-Cre;FAKfl/fl mice induced an
increase in activated HSCs42. More importantly, our present
data identifies a role for haematopoietic FAK in controlling
myeloid lineage commitment programme and raised the question
of whether this could be the main driver of the tumour metastasis
observed.
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Figure 7 | Gr1 cells govern tumour cell colonization in RERTFAKKO mice. B16 tumour cells, previously labelled with red cell tracker CMTPX, were injected
via the tail vein into RERTFAKWT, RERTFAKKO, BMFAKWT and BMFAKKO mice. (a) Lungs were harvested 2–5 h and 48 h after tumour cell injection to
measure the numbers of tumour cells homing and colonizing in the lungs, respectively. Representative stereomicroscopic images of lung surfaces from
RERTFAKWT and RERTFAKKO mice are given. (b) Bar charts represent mean number of B16 cells mm 2 lung sectionþ s.e.m., n¼ 5 mice per genotype.
(c) Gr1 antibody-depletion of Gr1þ cells or CXCR4 inhibition with AMD3100 in RERTFAKWT and RERTFAKKO mice. Nonspecific IgG or PBS were used
as a control. Mice were then injected with red cell tracker CMTPX labelled B16 cells. Representative stereomicroscope images of fresh lungs from both
genotypes are given. (d) Bar chart shows fold change relative to IgG of mean number of B16 cells per lung area. n¼ 10–12 mice per test. (e) Single-cell
suspensions of blood from RERTFAKWT and RERTFAKKO mice 2 h post tumour cell injection via the tail vein were analysed by flow cytometry. Bar charts
show numbers of CD45þCD11bþGr1hiLy6Clo (PMN) in blood. n¼ 3–4 mice per genotype. (f) CXCR4 inhibition with AMD3100 effect in B16 colonization
to the lungs of RERTFAKWT and RERTFAKKO mice. Bar chart shows fold change relative to PBS of mean number of B16 cells per lung area. n¼ 10–16 mice
per test. Scale bar, (a,c) 500mm. NS, not statistically significant; *Po0.05; ***Po0.001, Student’s t-test.
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The changes in haematopoietic homeostasis that resulted in
increased CMP levels were reflected in the periphery by increased
mobilization of granulocytes into the circulation as described
before48,49. Increased numbers of granulocytic and monocytic
CD11bþGr1þ cells were observed in the blood and spleen of
tumour-initiated RERTFAKKO mice when compared with
controls. Overall our findings establish that haematopoietic
FAK is important for the regulation of circulating myeloid cell
numbers, which have been shown to correlate with metastasis
burden19,20.
Cell changes were also accompanied by significant increases in
CXCL12 and C5/C5a in the serum of RERTFAKKO mice, known
pro-metastatic cytokines that correlate with poor prognosis50,53.
Increase in CXCL12 serum levels have been observed in GATA-
1low mice, a phenotype consistent with the low GATA-1 levels
observed in FAKKO HSCs64. On the other hand, CXCL12 serum
increase was accompanied by elevated levels of its receptor
CXCR4 in FAKKO PMNs sorted from lung after tumour cell
injection. CXCR4 is a granulocyte homing receptor so this
suggests that stromal FAK deficiency induced not only a change
in PMN numbers, but also in their function. The high levels of
CXCR4 in FAKKO PMNs likely increase their propensity to
respond to CXCL12 and home to sites of metastasis. Indeed, this
has been shown to be one of the mechanisms that governs
granulocyte infiltration to drive metastasis50,51. Interestingly C5/
C5a has also been demonstrated to induce granulocyte
recruitment in inflammatory conditions65.
Conversely, analysis of lymphoid numbers within the lung at
early time points after tumour cell injection showed a decrease in
CD8 and CD4 T cells with no alterations in NK cell numbers in
RERTFAKKO and BMFAKKO mice when compared with
respective controls. Since no changes were observed in bone
marrow common lymphoid progenitors, this suggested that, in
contrast to myeloid cells, the recruitment of T cells to the lung
was impaired. Granulocytic and monocytic CD11bþGr1þ cells
are also referred to as MDSCs. MDSCs are characterized by their
ability to suppress CD8 and CD4 T cell proliferation and
cytotoxicity and suppress NK cell activity, which, together, are
thought to enhance metastasis23,24. Moreover C5/C5a has been
shown not only to increase the infiltration of MDSCs, but also
their immune suppressive properties, resulting in decreased
infiltration of CD8 T cells in tumours66. Our data corroborated
these findings and point towards a role for haematopoietic FAK
deficiency in increasing not only numbers, but also recruitment
of granulocytes to metastatic sites, thus generating a pro-
metastatic microenvironment27–29. In fact depleting Gr1þ cells
or inhibition of CXCR4 in RERTFAKWT and RERTFAKKO mice
before tumour cell injection was sufficient to reduce tumour cell
colonization in the lungs of RERTFAKKO mice to levels observed
in RERTFAKWT control mice. Thus our work shows that loss
of stromal FAK, via the upregulation of Gr1þ cell numbers
and CXCR4 signalling, induces a permissive microenvironment
at metastatic sites that facilitates the increased colonization
by tumour cells observed in RERTFAKKO and BMFAKKO
mice. These data suggest that the myeloid commitment and
recruitment of these cells to metastatic sites in RERTFAKKO mice
are a major driver of the elevated tumour cell colonization
observed.
In short, our findings establish a critical mean by which
FAK regulates metastasis. Decreasing FAK levels in the stromal
and haematopoietic compartment generates a pro-metastatic
microenvironment that increases tumour metastasis. Given
the importance of understanding the biology behind cancer
metastasis, the impact of our study lies in unfolding a mecha-
nism by which FAK in the stromal compartment regulates
metastasis.
Methods
Mice. FAKfl/fl mice30 were bred with RERTnERT/ERTCre31,32 mice provided by
Mariano Barbacid to generate FAKfl/fl mice that express CreERT2 under the control
of the large unit of RNA polymerase 2 (RERTnERT/ERTCre;FAKfl/fl) on a mixed
C57BL6/129 background. RERTnERT/ERTCre;FAKfl/fl and control FAKfl/fl mice were
bred with RIP-Tag2 mice33 provided by Douglas Hanahan generating RIP-
Tag2;RERTnERT/ERTCre;FAKfl/fl and RIP-Tag2;FAKfl/fl mice, respectively. WT mice
were maintained on a mixed C57/Bl6J/129 background, whereas RIP-Tag2 mice
used for transplantation experiments were maintained on a C57/Bl6J background
in standard ventilated cages in accordance with CR-UK and QMUL institutional
and Home Office guidelines. Male mice were used as bone marrow donors. All
experiments were approved by the Animal Research Ethics and United Kingdom
Coordination Committee on Cancer Research guidelines and Home Office
Regulations.
RIP-Tag2 model. RIP-Tag2;RERTnERT/ERTCre;FAKfl/fl and RIP-Tag2;FAKfl/fl mice
were induced with daily tamoxifen in the chow (Harlan) at 8–9 weeks of age and
were culled at 15 weeks of age.
Lethally irradiated RIP-Tag2 mice were transplanted with bone marrow cells
from male RERTnERT/ERTCre;FAKfl/fl or FAKfl/fl control mice at 6 weeks of age.
Mice were induced with tamoxifen treatment in the chow at 8–9 weeks of age and
were culled at 16 weeks of age.
At necropsy, pancreas with peri-pancreatic lymph nodes, liver and lungs were
fixed in 4% formaldehyde in PBS for subsequent immunohistochemical analysis.
Invasion grading and metastasis analysis were performed by staining for Tag as
described previously35. Paraffin-embedded sections of pancreas, liver and lungs
were permeabilized in citrate buffer, blocked in 5% normal goat serum, incubated
with rabbit anti-mouse large T cell antigen (Santa Cruz Biotechnology) antibody
(1:200 dilution) overnight at 4 C and anti-rabbit biotinylated secondary antibody
(1:200 dilution) for 45 min at RT. ABC reagents (Vector Labs) were added and
staining developed with DAB (Vector Labs) and couterstained with haematoxylin
(Sigma-Aldrich). Five step-wise sections, 100mm apart were analysed per tissue for
all mice.
Experimental metastasis assays. RERTnERT/ERTCre;FAKfl/fl or RERTnERT/
ERTCre control mice were given 3 mg of tamoxifen (Sigma-Aldrich) by gavage for 5
consecutive days and then daily tamoxifen in the chow until the end point of the
experiment. Bone marrow transplanted mice were treated with tamoxifen starting
2–3 weeks post transplant. After 5–7 days of tamoxifen treatment, 0.5 106
tumour cells (B16F0 or B16F10—ATCC, mycoplasma free) resuspended in 100 ml
of PBS were injected via the tail vein. Mice were examined for metastases at
necropsy. Tissues were either fixed in 4% formaldehyde in PBS or snap-frozen in
isopentane cooled in liquid nitrogen for subsequent immunohistochemical
analysis.
Bone marrow transplantation. Female mice of at least 6–12 weeks of age were
g-irradiated with 2 500 rad doses, 3 h apart, to ablate the endogenous bone
marrow. They were immediately rescued by tail vein injection of 1 106 freshly
isolated bone marrow cells from male RERTnERT/ERTCre;FAKfl/fl or RERTnERT/
ERTCre control mice resuspended in 0.1 ml sterile PBS. The mice were treated with
enrofloxacin (Baytril, Bayer) until 2 weeks after bone marrow transplantation.
RIP-Tag2 mice were transplanted at 6 weeks of age.
Flow cytometry. At different time points, mice were killed and cells isolated from
bone marrow, blood, lungs and spleen, and cell surface phenotypes were deter-
mined by direct immunofluorescence staining with conjugated antibodies for
mouse haematopoietic lineage-efluor450 and the anti-mouse antibodies CD117
(c-Kit)-APC, CD135 (Flt3)-PE, CD34-PE, CD16/32-PE-Cy7, CD45-efluor450,
Gr1-FITC, Ly6C-APC and CD11b-PE (eBiosciences) and Ly6-A/E (Sca-1)-PerCP-
Cy5.5 antibodies (Biolegend) all used at 1:100 dilution. Data were collected and
analysed using the BD LSRII and FlowJo softwares.
HSC isolation. HSCs were isolated from lineage depleted or c-Kit-enriched bone
marrow as described in refs 67, 68, using Miltenyi magnetic columns separation
kits. The cells obtained were then stained with streptavidin PE-Cy7 (Biolegend)
(lineage depleted cells) or lineage cocktail antibodies (BD Pharmingen) followed by
streptavidin PE-Cy7 (c-Kit-enriched cells) plus anti-mouse c-kit-APC and Ly6-A/E
(Sca-1)-Pacific Blue antibodies (Biolegend). Subsequently, Sca1þ c-KitþLin
(HSC) cells were isolated using a fluorescence-activated cell sorting Aria (Becton
Dickinson, Franklin Lakes, NJ).
Lung PMN isolation. Single-cell suspensions of lung were obtained by mincing
tissue and digesting in HBSS (without Ca, Mg) plus collagenase IV (2 mg ml 1)
(Gibco) for 20 min at 37 C, followed by 5 mM EDTA to stop the reaction and
forcing through a 70-mm cell strainer. After lysing the red blood cells and washing
in PBS with 2% fetal bovine serum, cells were blocked with Fc block (BD
Pharmingen) for 15 min at 4 C followed by incubation with the following antibody
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mix: CD45-efluor450, Gr1-FITC, Ly6C-APC and CD11b-PE (eBiosciences). Sub-
sequently, CD45þCD11bþGr1hiLy6Clo (PMN) cells were isolated using a fluor-
escence-activated cell sorting Aria (Becton Dickinson).
Gene expression analysis. RNA was extracted from HSC and PMN using the
RNeasy Micro Kit (Qiagen) and recommended protocol. cDNA syntesis was per-
formed in 20–50 ng of RNA using the Sensiscript RT Kit (Qiagen) according to
manufacturer’s instructions. For real time PCR each 20 ml reaction contained test
cDNA (1–2 ml), 10 ml Platinum SYBR Green qPCR SuperMix-UDG with Rox
(Invitrogen), 300 nM of each forward and reverse primer and nuclease free H2O in
an individual well of a 96-well plate. The following primer sets were used per
reaction: GAPDH fw (50-CTGCACCACCAACTGCTTAG-30) and GAPDH rev
(50-GTCTTCTGGGTGGCAGTGAT-30); FAK fw (50-AACAGCTATTTGATTTCT
TCTCAAAGT-30) and FAK rev (50-TCTTTTGCTAGATGCTAGGTATCTGT-30);
PU.1 fw (50-CGGATGACTTGGTTACTTACG-30) and PU.1 rev (50-GTAG-
GAAACCTGGTGACTGAG-30)69; Gata-1 fw (50-ATTCCTGGGGGCTCACCTT
ATG-30) and Gata-1 rev (50-TCCACAGTTCACACACTCTCTGGC-30)69; CXCR4
fw (50-TCCAACAAGGAACCCTGCTTC-30) and CXCR4 rev (50-TTGCCGACTA
TGCCAGTCAAG-30).
The following conditions were used to run the PCR amplification process: 50 C
for 2 mins, denaturation at 95 C for 10 mins followed by 40 cycles at 95 C for 15 s
and 1 min annealing/extension at 60 C. Data analyses were accomplished using the
StepOne Plus Real Time PCR machine (Applied Biosystems). Data were
normalized to endogenous GAPDH and fold changes in gene expression were
calculated using the comparative CT method.
Immunofluorescence. For immunofluorescence staining for Gr1, 5 mm frozen
lung sections were fixed in 100% acetone for 10 min, blocked in 5% normal goat
serum (Sigma-Aldrich) for 1 h, incubated with rat anti-Gr1 (clone RB6-8C5—BD
Pharmingen) primary antibody (1:50 dilution) overnight at 4 C and anti-rat
Alexa-Fluor-488 (Molecular Probes) secondary antibody (1:200 dilution) for
45 min at room temperature and finally mounted with Prolong anti-fade with 40 ,6-
diamidino-2-phenylindole (DAPI; Molecular Probes). Gr1þ cell numbers were
quantified microscopically in at least five different fields per section. Values are
given relative to total number of cells as assessed by the DAPI signal.
Cytokine analysis in serum. At indicated time points mice were killed, blood
collected by heart puncture, left to clot for 2 h at room temperature and centrifuged
at 2,000 g for 20 min. Mouse cytokine arrays (Proteome Profiller ARY006—R&D
Systems) were processed according to manufacturer’s instructions using 100 ml of
serum per membrane. Pixel analysis was used for quantification using Image J
software.
In vivo homing/colonization assays. B16F0 cells, previously labelled with red cell
tracker CMTPX (Molecular probes, Invitrogen, Life Sciences), were resuspended at
0.5 106 cells per 100ml of PBS and injected via the tail vein into mice. At 2 or 48 h
post inoculation, mice were killed and lungs fixed in 4% paraformaldehyde. Lungs
were dissected, photographed using a Leica MZ16F fluorescence stereomicroscope,
snap-frozen in OCT (OCT Killik, Bio-Optica, IT) and 5 mm cryosections were
prepared for analysis. Total numbers of red fluorescent tumour cells were quan-
tified and normalized for the total number of DAPI-positive nuclei for each section
using a Zeiss Axioplan microscope (Zeiss).
Gr1 depletion experiments. Mice were given 50 mg of rat anti-mouse Gr1 anti-
body (RB6-8C5, eBiosciences) or rat anti-mouse IgG2b k isotype control antibody
(eBiosciences) in 100 ml PBS one day before and on the day of tumour cell injection.
Homing/colonization assays were performed as described in the In vivo homing/
colonization assays section.
CXCR4 inhibition experiments. Mice were given 5 mg kg 1 of AMD3100
(Sigma) or PBS intraperitoneal on the day of tumour cell injection and following
days until harvesting. Homing/colonization assays were performed as described in
the In vivo homing/colonization assays section. At 48 h time point mice were
harvested within 60–90 min after inhibitor treatment.
Statistical analysis. Results are presented as means±standard error of the mean
(s.e.m.) for at least 2–3 independent experiments, unless otherwise stated. The
sample sizes used were based on level of changes and consistency expected. Sta-
tistical significance was reported as appropriate. Experimental metastasis and RIP-
Tag2 data analysis of statistical significance was performed using nonparametric
Mann–Whitney and w2 tests. All other data sets were analysed for statistical sig-
nificance using Student’s t-test. For both tests Po0.05 was considered statistically
significant. Sample sizes were chosen on the basis of the level of changes expected.
No randomization methods were used. During animal experiments, the investi-
gator was blinded to the genotype of the animals under study.
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